proxicromil

Proxicromil (FPL 57787) is an orally active chromone derivative developed in the late 1970s as a mast cell stabilizer for the treatment of allergic conditions such as asthma and atopic dermatitis. It acts by inhibiting the degranulation of mast cells, thereby preventing the release of histamine and other inflammatory mediators. Proxicromil was designed to be a more lipophilic and systemically available alternative to disodium cromoglycate (Intal). Despite showing some efficacy in clinical trials for asthma and atopic dermatitis, it was never marketed due to concerns about possible carcinogenicity and hepatotoxicity observed in animal studies. The drug was also investigated for migraine prophylaxis but showed no significant effect[1][2][3][8].

Other names

FPL 57787FPL57787FPL-57787chromone-2-carboxylic acid derivativechromone2-carboxylic acid derivativechromone 2-carboxylic acid derivative